Global Brain — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Craif develops biomarker analysis and AI-driven diagnostic solutions to enable early disease detection and personalized treatment through non-invasive testing of body fluids.
AI & Machine LearningBiotechHealthtechMedical DevicesTokyo, JP
Ryuichi Onose(Executive Officer, Director)inYuki Ichikawa(Director)Mika Yui(Director)
Co-investors1955 CapitalAozora Corporate Investment
Zafrens develops a unified drug discovery platform that integrates isolation, imaging, and sequencing workflows to accelerate the identification of therapeutic compounds across modalities.
AI & Machine LearningBiotechDeep TechSan Diego, US
Martin SmrcinainMaina NdunguinSwamy Vijayan(Executive Officer, Director)inYi ZhanginVikas Goelin
BoardJustin Briggsin
Co-investorsAcequia Capital (AceCap)BlueYard CapitalIaso VenturesRaptor GroupFoundersX Venturesimec.xpand+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.